Table 4. Univariate analysis of overall survival and time to progression in MPM patients treated with IL-2.
| Features | No. of patients | Overall survival P-value | Time to progression P-value |
|---|---|---|---|
| Age (41–77 mean 61.8) median 62.5 | |||
| ⩽62 | 30 | ||
| >62 | 30 | NS | NS |
| Gender | |||
| Male | 51 | NS | NS |
| Female | 9 | ||
| IMIG stage | |||
| IB+II | 1+14 | NS | NS |
| III | 42 | ||
| Histologic subtypes | |||
| Epithelioid | 46 | ||
| Biphasic | 9 | 0.02 | 0.02 |
| Sarcomatoid | 5 | ||
| ECOG performance status | |||
| 0 | 8 | ||
| 1 | 32 | NS | NS |
| 2 | 17 | ||
| Tryptase MCs | |||
| Low | 16 | 0.02 | 0.01 |
| High | 44 | ||
| Chymase MCs | |||
| Low | 33 | NS | NS |
| High | 27 | ||
| MVC (CD34) | |||
| Low | 30 | NS | NS |
| High | 30 | ||
| FoxP3 | |||
| Low | 29 | 0.000002 | 0.0039 |
| High | 29 | ||
| CD4 | |||
| Low | 24 | NS | NS |
| High | 24 | ||
| CD8 | |||
| Low | 29 | NS | NS |
| High | 28 | ||
| VEGF | |||
| Low | 28 | NS | NS |
| High | 30 | ||
Abbreviations: IMIG=International Mesothelioma Interest Group; ECOG=Eastern Cooperative Oncology Group; MCs=mast cells; MVC=microvessel count; MPM=malignant pleural mesothelioma; NS=not significant. Bold values indicate P<0.05.